Skip to main content
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
Loading...
Media
< Back
Media
Press Releases
Investors
Partnering
Careers
< Back
Careers
Careers
Working at Ipsen
All
Stories
Press Releases
Documents
Events
Updates
Other
Press shift tab to select search category
X
Loading...
United States
< Back
Global
EN
FR
Annual Report
EN
FR
Americas
Asia Pacific
Europe
Middle East & Africa
United States
Brazil
Canada
Mexico
Australia
China
Singapore
South Korea
Japan
Belgium
Ukraine
UK
Germany
France
Nordics
Greece
Italy
Netherlands
Spain
Poland
Russia
Czech Republic
Switzerland
Austria
UAE & Gulf
Saudi Arabia
Home
Company
< Back
Company
Who We Are
Leadership
Our History
Science
< Back
Science
Areas of Focus
Products
Clinical Trials
R&D
Grant Requests
Investigator Sponsored Studies
Responsibility
< Back
Responsibility
Responsibility
Environment
People
Governance
Charitable Donations
Patients
< Back
Patients
Patients
Early Access Public Policy
Stories
Study Indication:
Gastroenteropancreatic Neuroendocrine Tumors
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
X
You are now leaving the Ipsen US website. To continue, please click on
continue
.